Recent Updates — CLVLY

Clinuvel Pharmaceuticals Limited announced that its American Depositary Shares (ADS) commenced trading on the Nasdaq Stock Market on July 20, 2026, under the ticker symbol CUVL. This transition marks the company's uplift from a Level I American Depositary Receipt (ADR: CLVLY) to a Level II program. The company is listed on both the Australian Securities Exchange (ASX: CUV) and the Nasdaq. Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on developing therapies for genetic, metabolic, and dermatological disorders.

Clinuvel Pharmaceuticals Limited announced that its American Depositary Shares (ADS) are expected to commence trading on the Nasdaq Global Select Market under the ticker symbol CUVL on July 20, 2026. This follows the SEC declaring the company's Form 20-F registration statement effective on July 17. The move upgrades the company's existing over-the-counter ADR (CLVLY) from Level I to Level II. Each CUVL ADS represents one ordinary share listed on the Australian Securities Exchange. The company does not intend to raise capital or issue new shares through this program. Clinuvel is a biopharmaceutical company that develops therapies for genetic, metabolic, and dermatological disorders.